Novacyt S.A. Replacement Result of AGM (1044G)
19 Julio 2019 - 02:12AM
UK Regulatory
TIDMNCYT
RNS Number : 1044G
Novacyt S.A.
19 July 2019
The following amendments have been made to the announcement
released on 19 July 2019 at 7:03BST under RNS No 0930G:
Changed the words "today" to "yesterday" in the first and second
paragraphs.
All other details remain unchanged. The full amended text is
shown below.
Novacyt S.A.
("Novacyt" or the "Company")
Results of AGM and EGM Update
Paris, France and Camberley, UK - 19 July 2019 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in
clinical diagnostics, announces that all resolutions proposed at
the Annual General Meeting, held yesterday, were duly passed.
The Company also met yesterday to hold its Extraordinary General
Meeting (EGM). The meeting was not deemed quorate due to the
required minimum number of voting rights under French company law
not being present or represented at the meeting. Consequently, the
Company will reconvene an EGM at a later date.
- End -
For further information, please refer to www.novacyt.com or
contact:
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
SP Angel Corporate Finance LLP (Nominated Adviser and Joint
Broker)
Matthew Johnson / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång
+44 (0) 203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell/ Mary Whittow
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com/victoria.fostermitchell@fticonsulting.com/
Mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high quality assays
and reagents worldwide. The Group directly serves oncology,
microbiology, haematology and serology markets as do its global
partners, which include major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGGMGMNNLKGLZG
(END) Dow Jones Newswires
July 19, 2019 03:12 ET (07:12 GMT)
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024